Fritextsökning
Innehållstyper
-
Life science trends 2025 – Neurology
New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver active substances across the blood-...
-
Rising interest in CRISPR treatments
Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.
-
Meet us at Control 2025
Innovations that drive efficiency.
-
Pulsen på patientförbunden del 1: Schizofreni
Schizofreniforskningen gör framsteg, bland annat genom en ökad förståelse för könsspecifika skillnader i behandlingsbehov. Nu efterlyser Schizofreniförbundet ny...
-
Thomas Eldered: ”Innovation is the key”
Thomas Eldered speaks in a web clip about the challenges facing the life science sector in the future and what he, as an investor, finds most interesting in new companies.
-
How the Foreign Office will promote Swedish life science exports
The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...
-
Improving Nano-Structured Surfaces for Implants with Scanning Electron Microscopy
Promimic, a Swedish company specializing in the development and marketing of nano-structured surfaces for implants, heavily relies on scanning electron microscopes.
-
Sepsisbolag tar in kapital
Bioteknikbolaget Aptahem, som utvecklar en behandling mot sepsis, har beslutat om en företrädesemission som kan ge bolaget upp till 34,6 miljoner kronor.
-
Cancer researcher: “We can do better and reduce suffering”
Lund University researcher Catharina Hagerling is developing innovative methods to understand metastatic cancer, aiming to create more targeted treatments for p...
-
The art of successful licensing – “A lot has to align”
Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...
-
Astra Zeneca riskerar mångmiljonböter i Kina
Astra Zeneca kan tvingas betala upp till 77 miljoner kronor i böter för misstänkta obetalda importskatter i Kina, samtidigt som bolaget försöker återvinna förtr...
-
Setback for pharmaceutical companies in the Zantac case
A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.
-
Siemens köper forskningsplattform inom läkemedel för 51 miljarder
Siemens AG tar ett rejält kliv in på life science-området genom att förvärva amerikanska Dotmatics och dess forskningsplattform i en affär på 5,1 miljarder doll...
-
ZEN core now available for all ZEISS scanning electron microscopes
Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.
-
Aqilion's licensing journey: From Merck partnership to new opportunities
Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
Career coach on salaries: “There is no right or wrong”
What is a reasonable salary for my job? It's a question we all ask ourselves. But how important is a higher salary really? Career coach Tina Persson believes th...
-
Quality solutions for medical device R&D applications
From R&D to the quality assurance of series production in medical device manufacturing.
-
Explore our tailored program for Control 2025
Choose an innovation tour, or join our industry-specific guided tours.
-
CT technology for when the inside matters
ZEISS METROTOM 1 now at #HandsOnMetrology.
-
Tar in kapital för att genomföra cancerstudie
Det danska biotechbolaget Scandion Oncology genomför en nyemission som kan ge upp till 60 miljoner kronor. Huvudsyftet är att finansiera en klinisk studie i kolorektalcancer.
-
Life science trends 2025 – Part 1 obesity drugs
More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...
-
Cantargias vd slutar på dagen – han tar över
Cantargias vd Göran Forsberg avgår med omedelbar verkan. Styrelseledamoten Damian Marron går in som tillförordnad vd.
-
Danish obesity success causes recruitment problems in southern Sweden
The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.